A Pilot Study Assessing the Effect of Lymphaticovenous Micro-Anastomosis in the Treatment of Postmastectomy Lymphedema
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02020837 |
Recruitment Status :
Terminated
(Halted prematurely due to low enrollment)
First Posted : December 25, 2013
Results First Posted : April 9, 2018
Last Update Posted : June 27, 2018
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Lymphedema Post Mastectomy | Procedure: Lymphaticovenous Micro-Anastomosis | Early Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 2 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Intervention Model Description: | A lymphatic diversion with lymphaticovenous microanastomosis will be performed. |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Pilot Study Assessing the Effect of Lymphaticovenous Micro-Anastomosis in the Treatment of Postmastectomy Lymphedema |
Study Start Date : | September 2014 |
Actual Primary Completion Date : | December 3, 2015 |
Actual Study Completion Date : | July 2017 |
Arm | Intervention/treatment |
---|---|
Experimental: Lymphaticovenous Micro-Anastomosis |
Procedure: Lymphaticovenous Micro-Anastomosis |
- Changes Relative to Baseline in the Volume of the Affected Limb at 3 and 6 Months From Surgery [ Time Frame: 3 and 6 months from surgery ]Lymphatic Volumetric Assessment. Evaluation of the volumetric change, relative to baseline measurement, in the volume of the affected limb at 3 and 6 months from the procedure.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subject is 18-70 years of age
- Subject is Stage II-IV unilateral lymphedema
Exclusion Criteria:
- Subject is less than 6 months from completion of cancer treatment
- Subject has allergic reaction to the lymphatic contrast agent (Indocyanine Blue)
- Subject is medically unfit for the procedure
- Subject is unable to complete the follow-up visits
- Women with a positive urine pregnancy test are excluded from this study; women of childbearing potential (defined as those who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 consecutive months) must agree to refrain from breast feeding and practice adequate contraception as specified in the informed consent. Adequate contraception consists of oral contraceptive, implantable contraceptives, injectable contraceptives, a double barrier method, or abstinence.
- Subject has bilateral lymphedema

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02020837
United States, Arkansas | |
University of Arkansas for Medical Sciences | |
Little Rock, Arkansas, United States, 72205 |
Principal Investigator: | Mauricio Moreno, MD | University of Arkansas |
Responsible Party: | University of Arkansas |
ClinicalTrials.gov Identifier: | NCT02020837 |
Other Study ID Numbers: |
202676 |
First Posted: | December 25, 2013 Key Record Dates |
Results First Posted: | April 9, 2018 |
Last Update Posted: | June 27, 2018 |
Last Verified: | April 2018 |
Lymphedema Breast Cancer Lymphedema Lymphatic Diseases Postoperative Complications Pathologic Processes |